TAK-632抑制剂生物数据说明书M2235
棉花腺苷高半胱氨酸水解酶cDNA的克隆、表达及染色体定位
作物学报 ACTA AGRONOMICA SINICA 2008, 34(6): 958−964/zwxb/ISSN 0496-3490; CODEN TSHPA9E-mail: xbzw@基金项目: 国家自然科学基金项目(30471104); 国家重点基础研究发展计划(973计划)项目(2002CB111303); 教育部新世纪优秀人才项目(NCET-04-0500); 教育部111引智计划(B08025)作者简介: 佘义斌(1981−), 男, 江苏人, 硕士, 从事作物遗传育种研究; 朱一超(1980−), 男, 江苏人, 在读博士, 从事棉花遗传学研究。
** 同等贡献。
*通讯作者(Corresponding author): 郭旺珍。
E-mail: moelab@Received(收稿日期): 2007-08-15; Accepted(接受日期): 2008-01-15.DOI: 10.3724/SP.J.1006.2008.00958棉花腺苷高半胱氨酸水解酶cDNA 的克隆、表达及染色体定位佘义斌** 朱一超** 张天真 郭旺珍*(南京农业大学作物遗传与种质创新国家重点实验室, 江苏南京210095)摘 要: 腺苷高半胱氨酸水解酶是调节细胞内甲基反应的一个关键酶。
通过对高品质纤维陆地棉品系7235的棉纤维混合cDNA 文库随机测序, 得到一个棉花腺苷高半胱氨酸水解酶(编号: g073a03a,GhSAHH)的cDNA 序列。
该cDNA 序列长1 598 bp, 利用5′RACE 技术得到上游318 bp 的片段,序列拼接获得全长为1 916 bp 的cDNA 序列, ORF 为1 458 bp, 编码485个氨基酸, 其理论上的等电点p I ＝5.69, 分子量MW ＝53.2 kD 。
该基因在不同组织、器官中均表达, 在根、下胚轴和纤维发育早期优势表达。
根据Southern 杂交结果推测GhSAHH 基因在陆地棉基因组中为单拷贝。
普罗霉素产品安全技术说明书
________________________________________________________________________________________________________安全技术说明书第 1 部分： 物质/混合物及公司/企业的标识物质或混合物标识产品代码A1113803产品名称Puromycin公司/企业标识紧急电话号码1800 636 327 (Australia)0800 636 327 (New Zealand)866-536-0631 (US)Life Technologies Corporation 5781 Van Allen Way PO Box 6482Carlsbad, CA 92008+1 760 603 7200Life Technologies Korea11&12 FL, Suseo Office Building 281 Gwangpyeong-ro, Gangnam-gu Seoul, 135-884, Korea T 82.2.2023.0600Guangzhou OfficeRoom1010-1015 South TowerGuangzhou World Trade Center Complex 371-375 HuanShi Dong Rd Yuexiu DistrictGuangzhou 510095, China Tel: +86-020-8760 9229Hotline: 800 830 2001Fax: +86-020-8775 0687Life Technologies Co. Ltd8F., No. 123, Sec. 2, Zhongxiao E. Rd.Zhongzheng District, Taipei City 10058 Taiwan Tel: +886-2-2358 2838Fax: +886-2-2358 2839Life Technologies New Zealand Limited 18 - 24 Botha Road PenroseAuckland 1061NEW ZEALAND +64 9 579 30240800 636 327Life Technologies Australia Pty Limited 5 Caribbean Drive Scoresby VIC 3179AUSTRALIA +61 3 9262 37001800 636 327Room 1711 Beijing Silver Tower #2 DongSanHuan North Rd,ChaoYang District,Beijing, China 100027Tel: +86-010-8446 1800Fax: +86-010-6410 6617________________________________________________________________________________________________________301-431-8585 (US)++1-301-431-8585 (Outside of the U.S.) Country specific Emergency Number (if available):Research Use Only. Not for use in diagnostic procedures.第 2部分： 危害标识澳洲的物料安全数据表声明根据澳大利亚劳动安全局标准分类.危害性物质。
CaMKII是RIP3的一种底物,介导缺血和氧化应激诱导的心肌坏死
Ripk3-/- 挽救DOX所致心肌损伤（小剂量）
与 WT 对照相比，Ripk3-/- 小鼠中慢性 Dox 处理（5 mg/kg i.p. 每周一次，持续 4 周）诱导的心肌坏死死亡、纤维化和收 缩功能障碍显著改善
Dox或H/R处理RIP3上调
பைடு நூலகம்
Dox 处理或缺氧-复氧 (H/R)，一种在培养的心肌细胞中模拟体内 I/R 的条件，在 mRNA 和蛋白水平增加 RIP3 表达 2-3 倍
CaMKII 显性负性突变体 (CaMKII-DN) 的表达减弱了 H/R-和 Dox 诱导的心 肌细胞坏死，与 KN-93 相似
CaMKII-DN或 KN-93缓解了 RIP3 过表达诱导的心肌坏死性凋亡
RIP3与CaMKII免疫共沉淀
免疫共沉淀实验揭示了 RIP3 和 CaMKII 之间的物理相互作用，H/R（缺氧 9h 后再 给氧 1h）或 Dox 处理（1 M 处理 4h）明显增强了这种相互作用。此外，使用免疫 荧光共聚焦显微镜，我们在 Ad-RIP3 和 Ad-CaMKII 感染的心肌细胞和小鼠心肌中 观察到 RIP3 和 CaMKII 的大量共区域化。值得注意的是，I/R（或 H/R，细胞内） 或 Dox 处理明显增加了 RIP3 和 CaMKII 的共区域化，与它们的可诱导免疫共沉淀 一致。
通过免疫细胞化学评估RIP3表达
RIP3上调产生影响不受RIP1和MLKL调控
腺病毒载体过表达 RIP3 (Ad-RIP3) 以剂量依赖性方式导致坏死，表现为细胞活力严 重下降（通过 ATP 水平评估）和细胞膜完整性丧失（通过 LDH 释放评估）
RIP1 抑制剂 necrostatin-1 (Nec1) (23,24) 未能 消除 RIP3 诱导的心肌细胞坏死性凋亡证实了这 一结论
211274579_BS-400全自动分枝杆菌液体培养系统对分枝杆菌培养的效果评价
基金项目!浙江省医药卫生科技计划项目#-)-4T5(+F$ 作者单位!浙江大学医学院附属杭州市胸科医院临床检验实验 中心&杭州4()))X 通信作者蔡龙 ! &=>?'@!J?'@&1P4(<!L&C>?'@/J&>
Copyright©博看网. All Rights Reserved.
系统对疑似结核病患者临床标本中分枝杆菌的检测效能较高&具有较好的应用价值(
关键词分枝杆菌属%感染%培养技术%评价研究
中图分类号E4<,*+(
;6*-2*"(/%/0"'$$00$)"/0T!1O@@72"/5*"()M.)/,*)"$#(25U(V2(4G2-"2#$!.3"$5/% M.)/,*)"$#(25)2-"2#$ %'. %$(*("(*&)#( 1#2.(*&C,#(* Z'.:,#"&!">#$&!">'#(8'&M,$'\"(8#(*&+#"!$(*0 +7"(":#7!#P$3#4$38 +.(4.3&>#(*R,$'O,$3#:":>$-2"4#7B55"7"#4.94$M,.="#(*U("Q.3-"48C:,$$7$5;.9":"(.&>#(*R,$'GDEEEN&+,"(# +$33.-2$(9"(*#'4,$3!+#"!$(*&H/#"7!:#"7$(*GDF,$4/#"70:$/
精准医学药物治疗手册
个体化治疗基因检测套餐
1、支架PCI套餐：
（1）全面分析—1、2、60、62、152、106、120、168、6、8、10、13、62、67（氯吡格雷、阿司匹林、美托洛尔、辛伐他汀）
（2）部分分析—1、2、60、152、106、120、168、6、8、10、67（氯吡格雷、阿司匹林、美托洛尔、辛伐他汀）
10
坎地沙坦
64AGTR1(1166A>C)
I型血管紧张素II受体1166位点，靶点
64
AA基因型心衰患者，使用坎地沙坦治疗，疗效应答比AC、（CC）型好。
普罗帕酮
06CYP2D6(2850C>T)
细胞色素氧化酶2D6 2850位点多态性，代谢酶
6
1.PM 弱代谢型：减少70%剂量,记录ECG,监测血药浓度。
血小板糖蛋白IIIaPlA2多态性，靶点
120
1、GP IIIa PlA2：阿司匹林抵抗主要基因，CC基因型，行支架术后，其亚急性血栓事件发生率是TT型的5倍，需要更高剂量阿司匹林才能达到抗凝效果。此基因也涉及氯吡格雷抵抗，基因型意义同阿司匹林。
2、PEAR1 ：GG等位基因对阿司匹林抗血小板应答好； AA\AG基因型，用阿司匹林（或结合氯吡格雷），PCI患者，心梗和死亡率高。
抗高血压
美托洛尔
63ADRB1(1165G>C)
β-1肾上腺素受体，靶点
63
1、对于高血压，CC型(Arg389)，舒张压（DBP）降压效果最好（降9-15点），CG型较好（降1-6点），GG型降压效果不理想。收缩性心力衰竭患者，用美托洛尔或卡维地洛治疗；
2、对于没有阻塞性冠状动脉疾病的女性，GG基因型者，6年间出现心肌梗死的风险比达3.63，约为19%。
白杨素通过PI3K／AKT信号通路抑制LPS诱导的软骨细胞自噬
网络出版时间：２０２１－４－２２１７：０７：００ 网络出版地址：ｈｔｔｐｓ：／／ｋｎｓ．ｃｎｋｉ．ｎｅｔ／ｋｃｍｓ／ｄｅｔａｉｌ／３４．１０８６．Ｒ．２０２１０４２２．１４１２．０２６．ｈｔｍｌ白杨素通过ＰＩ３Ｋ／ＡＫＴ信号通路抑制ＬＰＳ诱导的软骨细胞自噬杨 阳１，何 宇２，史于传２，舒见威３，虞 乐３，胡 伟１（安徽医科大学第二附属医院１．药物临床试验研究中心、２．妇产科，３．麻醉与围术期医学安徽省普通高校重点实验室，安徽合肥 ２３０６０１）ｄｏｉ：１０．３９６９／ｊ．ｉｓｓｎ．１００１－１９７８．２０２１．０５．０１３文献标志码：Ａ文章编号：１００１－１９７８（２０２１）０５－０６６２－０７中国图书分类号：Ｒ ３３２；Ｒ２８５ ５；Ｒ３２９ ２４；Ｒ３９２；Ｒ６８４ ３；Ｒ９７７ ６摘要：目的 探索白杨素对脂多糖诱导的大鼠软骨细胞骨关节炎模型中对软骨细胞自噬的作用及其机制。
方法 提取１０只ＳＰＦ级ＳＤ大鼠关节软骨正常细胞进行体外分离培养，通过ＬＰＳ诱导大鼠软骨细胞自噬。
实验分为空白对照组、ＬＰＳ组、白杨素（ＣＨＲ）组和ＬＰＳ＋ＣＨＲ组；ＣＣＫ ８法检测各分组细胞的活性、Ｒｈｏｄａｍｉｎｅ１２３检测各组细胞中线粒体膜电位、ＤＣＦＨ ＤＡ检测各组细胞的活性氧，Ｗｅｓｔｅｒｎｂｌｏｔ法检测各组细胞中ＰＩ３Ｋ、ＡＫＴ、ｐ ＰＩ３Ｋ、ｐ ＡＫＴ、Ｂｅｃｌｉｎ １及ＬＣ３Ⅱ的蛋白表达。
结果 白杨素对ＬＰＳ诱导的软骨细胞自噬具有抑制作用，且当白杨素浓度为１０ｍｍｏｌ·Ｌ－１时抑制自噬作用最为显著；白杨素能够抑制ＬＰＳ所致ＬＰＳ诱导的软骨细胞的活性氧（ＲＯＳ）的增加；白杨素抑制了细胞受损后线粒体膜电位的降低；同时白杨素抑制Ｂｅｃｌｉｎ １、ＬＣ３Ⅱ蛋白的表达，抑制ＰＩ３Ｋ和ＡＫＴ的磷酸化。
结论 白杨素可能通过抑制ＰＩ３Ｋ／ＡＫＴ信号通路，下调自噬蛋白Ｂｅｃｌｉｎ １和ＬＣ３Ⅱ的表达抑制自噬，进而保护软骨细胞。
TAK-632_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :TAK-632Catalog No. :HY-15767CAS No. :1228591-30-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:TAK 632; TAK632Formula:C27H18F4N4O3SMolecular Weight:554.52CAS No. :1228591-30-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
壳聚糖及其衍生物抗菌机理研究进展_林水森
· 222·
化学通报 2014 年 第 77 卷 第 3 期
［24 ］
http： / / www． hxtb． org
终抑制钛表面生物膜的形成。 Hilde 等 也采用 微阵列分析考察蜡样芽胞杆菌 （ ATCC 14579 ） 对 不同分子量和取代度的壳聚糖的转录响应性 。结 果表明， 经过壳聚糖处理的菌株的开放阅读框发
品保鲜、 伤口敷料和组织工程等方面 。本文综述了近年来在壳聚糖基材料抗菌模型 、 影响抗菌活性因素及抗 菌活性优化方案方面的研究进展 ， 希望对壳聚糖衍生物抗菌材料的制备及优化提供参考 。 关键词 壳聚糖 抗菌活性 抗菌机制
Progress in Antimicrobial Mechanism of Chitosan and Its Derivatives
化学通报 2014 年 第 77 卷 第 3 期
· 221·
22 细胞的超微结构变化， 菌发现在相互作用部 位出现部分细胞膜脱离细胞壁的现象， 产生“液 （ vacuolelike ） 结构， 泡样” 造成离子和水分子外 Ｒejane 流， 导致细菌内部压力下降而死亡。因此， 等 认为， 壳聚糖通过静电作用对微生物形成了 双重干扰， 一是改变了膜壁渗透性， 引起内部渗透
2
影响壳聚糖抗菌活性的因素
Kong 等［26］认为， 壳聚糖抗菌活性和作用模式
时， 参与编码甲壳素结合蛋白和糖异生的基因表 达均发生了显著性下调， 前者使得细菌对甲壳素 的利用受到限制， 后者使得非糖物质转化为糖， 均 ［25 ］ 。 Maria 有可能使细菌能量枯竭 等 研究发现， 相同浓度下， 壳寡糖 （ COS ） 比壳聚糖的抗真菌活 性更强。 赋 予 真 菌 COS 抗 性 的 基 因 研 究 表 明， AＲL1 基因 （ 一种 Ｒas 超家族的成员， 参与膜转运 调控） 的过度表达能够增强真菌对于 COS 的抗 性， 免于膜渗漏和损坏。同时， 他们还发现对 COS 具有抗性的真菌菌株， 仍然对两性霉素 B 、 氟康唑 和特比萘芬敏感， 而当 COS 与氟康唑合用于野生 真菌时， 两者具有协同抗菌作用。 COS 的基因作 用靶点使其区别于以真菌膜为作用靶点的其他抗 真菌剂， 预示着其可作为一种耐药真菌的杀菌剂 。 与 Zakrzewska 等 的研究比较， 虽然所选研究对 象和使用浓度不同， 但两组研究在细胞壁组织、 腺